599 filings
424B3
PRTG
Portage Biotech Inc
30 Apr 24
Prospectus supplement
6:23pm
6-K
PRTG
Portage Biotech Inc
30 Apr 24
Current report (foreign)
6:21pm
424B3
PRTG
Portage Biotech Inc
12 Apr 24
Prospectus supplement
5:22pm
6-K
PRTG
Portage Biotech Inc
12 Apr 24
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
5:21pm
424B3
PRTG
Portage Biotech Inc
8 Mar 24
Prospectus supplement
5:30pm
6-K
1d14sa
8 Mar 24
Current report (foreign)
5:04pm
424B3
t0lfe s2vth25
6 Mar 24
Prospectus supplement
9:36pm
6-K
jji4a2bhq8
6 Mar 24
Current report (foreign)
9:11pm
6-K
0cyca9dn2t2lv3drergf
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
424B3
id1d5j
28 Feb 24
Prospectus supplement
5:19pm
6-K
ge399 1ihr
28 Feb 24
Current report (foreign)
5:17pm
SC 13G
wuie0j
14 Feb 24
PORTAGE BIOTECH / ARMISTICE CAPITAL ownership change
3:50pm
424B3
rha1atxipj7z jreu
18 Jan 24
Prospectus supplement
5:41pm
6-K
58qnl12ggi nu5agvk
18 Jan 24
Current report (foreign)
5:09pm
424B3
zoeibb96
4 Jan 24
Prospectus supplement
5:49pm
6-K
e82xmu wn46pjfor1
4 Jan 24
Current report (foreign)
8:10am
S-8
rhb9 t3r7nl1mmsc4
1 Dec 23
Registration of securities for employees
4:05pm
424B3
9irks6kucdtwybh9qvi
28 Nov 23
Prospectus supplement
4:03pm
6-K
butfatboh
28 Nov 23
PORT 2 and 6 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
4:02pm
6-K
s3pdlt7ef0b18 49ca
28 Nov 23
Current report (foreign)
4:01pm